PD-L1 IHC 22C3 pharmDx
Interpretation Manual –
Non-small Cell Lung Cancer (NSCLC)

CE-IVD–marked for in vitro diagnostic use
For countries outside of the European Union, see the local KEYTRUDA product label for approved indications and expression cutoff values to guide therapy.
# Table of Contents

- **Intended Use** 04
- **Introduction** 06
- **PD-L1 Overview** 08
- **PD-L1 IHC 22C3 pharmDx Overview** 10
- **Kit Configuration (SK006)** 11
- **Technical Considerations** 12
  - Specimen Preparation 12
  - In-house Control Tissue 12
  - Optional Additional In-house Control: Tonsil Tissue 13
  - Tissue Processing 13
- **PD-L1 IHC 22C3 pharmDx Staining Procedure** 14
- **Technical Checklist** 16
- **Clinical Interpretation Guidelines** 17
  - General Considerations 17
  - Tissue Criteria 17
  - Evaluating Controls 17
  - Verify Sample Acceptability 21
- **Evaluate Staining and Determine Tumor Proportion Score** 22
  - Definition of Tumor Proportion Score (TPS) 22
  - Evaluation of PD-L1 Staining 22
  - Guidelines and Methods to Determine Tumor Proportion Score 22
- **Scoring Guidelines** 24
- **Suggested Methods for Determining TPS** 25
- **Identifying Patients with NSCLC for Treatment** 27
- **Reporting Results** 29
- **PD-L1 Staining Characteristics** 30
  - Key Considerations in Scoring PD-L1 IHC 22C3 pharmDx Stained Specimens 30
  - Image Guide for Interpretation of PD-L1 IHC 22C3 pharmDx Staining 31
- **PD-L1 IHC 22C3 pharmDx TPS < 1% Case Examples** 37
- **PD-L1 IHC 22C3 pharmDx TPS 1–49% Case Examples** 41
- **PD-L1 IHC 22C3 pharmDx TPS ≥ 50% Case Examples** 45
  - (TPS 40–60%) 52
- **PD-L1 IHC 22C3 pharmDx Near ≥ 50% Cut-off Case Examples** 57
  - (TPS 0–10%) 57
- **Artifacts** 62
- **Troubleshooting Guide** 69
- **Clinical Performance Evaluation** 70
  - KEYNOTE-024: Controlled trial of NSCLC patients naïve to treatment 70
  - KEYNOTE-010: Controlled trial of NSCLC patients previously treated with chemotherapy 72
- **References** 76
Intended Use

For in vitro diagnostic use. PD-L1 IHC 22C3 pharmDx is a qualitative immunohistochemical assay using Monoclonal Mouse Anti-PD-L1, Clone 22C3 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) and melanoma tissue using EnVision FLEX visualization system on Autostainer Link 48.

Non-Small Cell Lung Cancer (NSCLC)
PD-L1 protein expression is determined by using Tumor Proportion Score (TPS), which is the percentage of viable tumor cells showing partial or complete membrane staining at any intensity.
PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying NSCLC patients for treatment with KEYTRUDA® (pembrolizumab). See the KEYTRUDA® product label for expression cutoff values guiding therapy in specific clinical circumstances.
Introduction

PD-L1 IHC 22C3 pharmDx is the only trial-proven companion diagnostic CE-IVD–marked as an aid in identifying patients with NSCLC for treatment with KEYTRUDA® (pembrolizumab). This Interpretation Manual is provided as a tool to help guide pathologists and laboratory personnel in achieving correct and reproducible results in assessing PD-L1 expression in formalin-fixed, paraffin-embedded non-small cell lung cancer (NSCLC) specimens. Expression of PD-L1 can help identify patients for anti-PD-1 immunotherapy.

The manual provides detailed scoring guidelines and technical information from the PD-L1 IHC 22C3 pharmDx Instructions for Use (IFU) to ensure high-quality staining and diagnostic assessment. To help familiarize you with the requirements for scoring NSCLC stains with PD-L1 IHC 22C3 pharmDx, example cases of various PD-L1 expression levels are provided as reference. These example cases and in-depth recommendations for interpretation of PD-L1 IHC 22C3 pharmDx can help individual labs achieve reproducible and reliable results.

PD-L1 IHC 22C3 pharmDx is considered a qualitative assay; however, diagnostic status using PD-L1 expression requires the determination of percentage of stained tumor cells.

Non-small cell lung cancer tissue specimens that are tested for PD-L1 expression are scored and divided into three levels based on a Tumor Proportion Score (TPS):

- TPS < 1%: No PD-L1 expression
- TPS 1–49%: PD-L1 expression
- TPS ≥ 50%: High PD-L1 expression

PD-L1 expression levels are used to inform patient eligibility for treatment with KEYTRUDA.

For more details on staining and interpretation, please refer to the current version of the IFU provided with PD-L1 IHC 22C3 pharmDx, Code SK006 or visit www.agilent.com.
Assay Interpretation
The clinical interpretation of any staining, or the absence of staining, must be complemented by the evaluation of proper controls. Evaluation must be made by a qualified pathologist within the context of the patient’s clinical history and other diagnostic tests. This product is intended for in vitro diagnostic (IVD) use.

Reporting Results
To help understand what information should be reported to the treating physician, please refer to the Reporting Results section of this manual on page 29.

Photomicrographs
The included photomicrographs are of NSCLC unless otherwise noted. Photomicrograph magnification levels may appear different than indicated in respective annotations due to adjustment of image size.
PD-L1 Overview

The PD-1/PD-L1 Pathway Controls the Immune Response in Normal Tissue

Programmed death-ligand 1 (PD-L1) is a trans-membrane protein that binds to the programmed death-1 receptor (PD-1) during immune system modulation. The PD-1 receptor is typically expressed on cytotoxic T-cells and other immune cells, while the PD-L1 ligand is typically expressed on normal cells. Normal cells use the PD-1/PD-L1 interaction as a mechanism of protection against immune recognition by inhibiting the action of T-cells (Figure 1). Inactivation of cytotoxic T-cells downregulates the immune response such that the inactive T-cell is exhausted, ceases to divide, and might eventually die by programmed cell death, or apoptosis.

The Tumor Escapes Detection by Utilizing the PD-1/PD-L1 Pathway

Many tumor cells are able to upregulate the expression of PD-L1 as a mechanism to evade the body’s natural immune response. Activated T-cells recognize the PD-L1 marker on the tumor cell, similar to that of a normal cell, and PD-L1 signaling renders the T-cell inactive (Figure 2). The tumor cell escapes the immune cycle, continues to avoid detection for elimination, and is able to proliferate.

Anti-PD-1 Therapy Enables the Immune Response Against Tumors

KEYTRUDA® (pembrolizumab) is an anti-PD-1 cancer immunotherapeutic that blocks the PD-1/PD-L1 interaction between tumor cells and activated T-cells (Figure 3). When the tumor cell is unable to interact with the activated T-cell, the immune system remains active, helping to prevent immunosuppression.

PD-L1 IHC 22C3 pharmDx Detects PD-L1 in NSCLC Specimens

Tumor PD-L1 upregulation and detection on tumor cells is a biomarker for response to anti-PD-1 therapy. PD-L1 IHC 22C3 pharmDx was the only companion diagnostic used in the KEYTRUDA clinical trials (KEYNOTE-010 and KEYNOTE-024), which investigated the clinical efficacy of KEYTRUDA in patients with NSCLC. KEYTRUDA is a humanized monoclonal PD-1-blocking antibody.
The PD-1/PD-L1 Pathway

**Figure 1:** Inactivation of T-cells limits damage to normal tissue.

**Figure 2:** Inactivation of T-cells reduces tumor cell death and elimination.

**Figure 3:** Blocking the PD-1/PD-L1 interaction helps to enable active T-cells and tumor cell death and elimination.
PD-L1 IHC 22C3 pharmDx Overview

What is PD-L1 IHC 22C3 pharmDx?
PD-L1 IHC 22C3 pharmDx is the only trial-proven companion diagnostic indicated as an aid in identifying patients with NSCLC for treatment with KEYTRUDA® (pembrolizumab). PD-L1 IHC 22C3 pharmDx is a qualitative immunohistochemical (IHC) assay intended for use in the detection of PD-L1 in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tissue samples using Autostainer Link 48.

PD-L1 IHC 22C3 pharmDx was the only assay used in the KEYTRUDA clinical trials to determine the PD-L1 expression of patients with NSCLC.

Components of PD-L1 IHC 22C3 pharmDx
PD-L1 IHC 22C3 pharmDx contains optimized reagents to perform an IHC staining procedure using a linker and a chromogen enhancement reagent (Figure 4).

Deparaffinization, rehydration, and target retrieval is performed using a 3-in-1 procedure on PT Link. Following peroxidase block, specimens are incubated with monoclonal mouse primary antibody to PD-L1 or the Negative Control Reagent. Specimens are then incubated with a Mouse LINKER, followed by incubation with a ready-to-use Visualization Reagent consisting of secondary antibody molecules and horseradish peroxidase molecules coupled to a dextran polymer backbone.

The enzymatic conversion of the subsequently added chromogen results in precipitation of a visible reaction product at the site of the antigen. The color of the chromogenic reaction is modified by a chromogen enhancement reagent. The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope.
Kit Configuration

PD-L1 IHC 22C3 pharmDx (Code SK006) contains reagents to perform 50 tests in up to 15 individual runs (Figure 5):

1. EnVision FLEX Target Retrieval Solution, Low pH (50x)
2. Peroxidase-Blocking Reagent
3. Primary antibody: Monoclonal Mouse Anti-PD-L1, Clone 22C3
4. Negative Control Reagent
5. Mouse LINKER
6. Visualization Reagent-HRP
7. DAB+ Substrate Buffer
8. DAB+ Chromogen
9. DAB Enhancer
10. PD-L1 IHC 22C3 pharmDx Control Cell Line Slides*

EnVision FLEX Wash Buffer, (20x) (Code K8007) and EnVision FLEX Hematoxylin (Code K8008) are required but not included in the kit.

* Dr. AF Gazdar and Dr. JD Minna at NIH are acknowledged for their contribution in developing NCI-H226 (ATCC Number: CRL-5826*).
Technical Considerations

Technical problems relating to the performance of PD-L1 IHC 22C3 pharmDx may stem from two areas: those involving specimen collection and preparation prior to performing the test, and those involving the actual performance of the test itself. Technical problems relating to the performance of the test generally are related to procedural deviations and can be controlled and minimized through training and, where necessary, clarification of the product instructions.

Specimen Preparation

Specimens must be handled to preserve the tissue for immunohistochemical staining. Determine intact tumor morphology and the presence of sufficient tumor cells for evaluation. Use standard methods of tissue processing for all specimens.

In-house Control Tissue

Differences in processing and embedding in the user’s laboratory may produce significant variability in results. Include positive and negative in-house control tissue in each staining run, in addition to the PD-L1 IHC 22C3 pharmDx Control Cell Line Slide.

Select positive and negative control tissue from fresh specimens of the same tumor indication as the patient specimen. Fix, process, and embed the control tissue in the same manner. Control tissues processed differently from the patient specimen validate reagent performance only and do not verify tissue preparation.

The ideal positive control tissue provides a complete dynamic representation of weak to moderate cell membrane staining. The ideal negative control tissue gives no staining on tumor cells but contains tumor-associated macrophages/immune cells which may express PD-L1 and offer an internal positive control.
Optional Additional In-house Control: Tonsil Tissue

Tonsil stained with PD-L1 should be pre-screened to exhibit strong staining in portions of the crypt epithelium and weak to moderate staining of the follicular macrophages in the germinal centers. PD-L1 expression of the endothelium, fibroblasts, as well as the surface epithelium should be negative.

Tissue Processing

Formalin-fixed, paraffin-embedded tissues have been validated for use. Block specimens into a thickness of 3 mm or 4 mm, fix in formalin and dehydrate and clear in a series of alcohols and xylene, followed by infiltration with melted paraffin. The paraffin temperature should not exceed 60 °C. Studies were performed with fixation in 10% neutral buffered formalin for 12–72 hours. Fixation times of 3 hours or less should not be used for PD-L1 assessment. The use of PD-L1 IHC 22C3 pharmDx on decalcified tissues or other fixatives has not been validated and is not recommended.

Cut tissue specimens into sections of 4–5 µm. After sectioning, tissues should be mounted on Dako FLEX IHC microscope slides (Code K8020) or Fisherbrand Superfrost Plus slides and then placed in a 58 ± 2 °C oven for 1 hour. Store tissue sections in the dark at 2–8 °C (preferred) or at room temperature up to 25 °C to preserve antigenicity, and stain within 6 months of sectioning.
PD-L1 IHC 22C3 pharmDx Staining Procedure

The PD-L1 IHC 22C3 pharmDx reagents and instructions have been designed for optimal performance. Further dilution of the reagents, alteration of incubation times, temperatures, or materials may give erroneous results. All of the required steps and incubation times for staining are pre-programmed in the DakoLink software.

Reagent Storage

Store all components of PD-L1 IHC 22C3 pharmDx, including Control Cell Line Slides, in the dark at 2–8 °C when not in use on Autostainer Link 48.

Reagent Preparation

Equilibrate all components to room temperature (20–25 °C) prior to immunostaining. Do not use after the expiration date printed on the outside of the package.

EnVision FLEX Target Retrieval Solution, Low pH

Dilute EnVision FLEX Target Retrieval Solution, Low pH, 50x 1:50 using distilled or deionized water (reagent-quality water). One 30 mL bottle of concentrate provides 1.5 L of working solution, which is sufficient to fill one PT Link tank. Discard EnVision FLEX Target Retrieval Solution, Low pH after 3 uses or 5 days after dilution.

EnVision FLEX Wash Buffer

Dilute EnVision FLEX Wash Buffer, 20x 1:20 using distilled or deionized water (reagent-quality water). Store unused 1x buffer at 2–8 °C for no more than one month. Discard if cloudy in appearance.

DAB+ Substrate-Chromogen Solution

Add 1 drop of DAB+ Chromogen per mL of DAB+ Substrate Buffer and mix. Prepared DAB+ Substrate-Chromogen is stable for 5 days if stored in the dark at 2–8 °C. Mix the DAB+ Substrate-Chromogen Solution thoroughly prior to use. Any precipitate developing in the solution will not affect staining quality.

- If using an entire bottle of DAB+ Substrate Buffer, add 9 drops of DAB+ Chromogen. Although the DAB+ Substrate Buffer label states 7.2 mL, this is the usable volume and does not account for the “dead volume” of DAB+ Substrate Buffer in the bottle
- The color of the DAB+ Chromogen may vary from clear to lavender brown. This will not affect the performance of the product. Dilute per the guidelines above. Adding excess DAB+ Chromogen to the DAB+ Substrate Buffer results in deterioration of the positive signal
Controls to Assess Staining Quality
Include one PD-L1 IHC 22C3 pharmDx Control Cell Line Slide stained with the primary antibody in each staining run. For each set of test conditions, include positive and negative in-house control tissue stained with the primary antibody in each staining run. Use the Negative Control Reagent in place of the primary antibody on a sequential section of each patient specimen.

Deparaffinization, Rehydration, and Target Retrieval
Use PT Link to perform a Deparaffinization, Rehydration, and Target Retrieval 3-in-1 procedure.
- Set Preheat and Cool to 65 °C, and set Heat to 97 °C for 20 minutes
- Fill PT Link tanks with 1.5 L per tank of EnVision FLEX Target Retrieval Solution, Low pH, working solution to cover the tissue sections
- Preheat the Target Retrieval Solution, Low pH to 65 °C
- Immerse Autostainer racks containing mounted, FFPE tissue sections into the preheated Target Retrieval Solution, Low pH in PT Link tank. Incubate for 20 minutes at 97 °C
- When incubation has been completed and the temperature has cooled to 65 °C, remove each Autostainer slide rack with slides from the PT Link tank and immediately place the slides into a tank (e.g., PT Link Rinse Station, Code PT109) containing room temperature EnVision FLEX Wash Buffer working solution
- Leave Autostainer rack with slides in room temperature EnVision FLEX Wash Buffer for 5 minutes

Staining and Counterstaining
- Place the Autostainer rack with slides on the Autostainer Link 48
- Ensure slides remain wet with buffer while loading and prior to initiating the run. Dried tissue sections may display increased non-specific staining
- Select the PD-L1 IHC 22C3 pharmDx protocol. The instrument performs the staining and counterstaining procedures by applying the appropriate reagent, monitoring the incubation time, and rinsing slides between reagents
- Counterstain slides using EnVision FLEX Hematoxylin, Code K8008

Mounting
Use non-aqueous permanent mounting media.
To minimize fading, store slides in the dark at room temperature (20–25 °C).
**Technical Checklist**

Use the checklist below to ensure correct usage of PD-L1 IHC 22C3 pharmDx:

Customer Name/Institution

Name and Title

Autostainer Link 48 Serial Number ................................. Software Version .................................

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Regular preventive maintenance is performed on the Autostainer Link 48 and PT Link?

PD-L1 IHC 22C3 pharmDx is used before the expiration date printed on the outside of the box?

All PD-L1 IHC 22C3 pharmDx components, including Control Cell Line Slides, are stored in the dark at 2–8 °C?

All PD-L1 IHC 22C3 pharmDx components, including Control Cell Line Slides, are equilibrated to room temperature (20–25 °C) prior to immunostaining?

Appropriate positive and negative control tissue from NSCLC are identified?

Tissues are fixed in neutral buffered formalin?

Tissues are infiltrated with melted paraffin, at or below 60 °C?

Tissue sections of 4–5 µm are mounted on Dako FLEX IHC Microscope Slides or Fisherbrand Superfrost Plus charged slides?

Specimens are oven-dried at 58 ± 2 °C for 1 hour?

Specimens are stained within 6 months of sectioning when stored in the dark at 2–8 °C (preferred) or at room temperature up to 25 °C?

EnVision FLEX Target Retrieval Solution, Low pH is prepared properly? pH of 1x Target Retrieval Solution must be 6.1 ± 0.2.

EnVision FLEX Wash Buffer is prepared properly?

DAB+ Substrate-Chromogen Solution is prepared properly?

Slides are counterstained with EnVision FLEX Hematoxylin?

The Deparaffinization, Rehydration, and Target Retrieval 3-in-1 procedure is followed using PT Link?

Slides remain wet with buffer while loading and prior to initiating run on Autostainer Link 48?

The PD-L1 IHC 22C3 pharmDx protocol is selected on Autostainer Link 48?

Do you have all the necessary equipment to perform the PD-L1 IHC 22C3 pharmDx according to protocol? If not, specify what is missing in comments below.

Additional observations or comments:
Clinical Interpretation Guidelines

General Considerations

PD-L1 IHC 22C3 pharmDx evaluation should be performed by a qualified pathologist using a light microscope. Details of the PD-L1 IHC 22C3 pharmDx scoring guidelines are reviewed on page 24. Before examining the patient specimen for PD-L1 staining, it is important to examine the controls to assess staining quality.

PD-L1 interpretation is best assessed by requesting 3 serial cut tissue sections (H&E, PD-L1 stain, and NCR stain) so that if the H&E is first assessed and acceptable, IHC staining of the remaining 2 serial cut sections are likely to retain the same favorable tissue criteria.

Each PD-L1 IHC 22C3 pharmDx is configured with Control Cell Line Slides that should be included in each IHC run. Guidelines on interpreting the Control Cell Line Slide are reviewed to the right. In-house control tissue slides should be assessed with every IHC run.

Tissue Criteria

Confirm the Presence of at Least 100 Viable Tumor Cells

A hematoxylin and eosin (H&E) stained section is recommended for the evaluation of an acceptable sample. PD-L1 IHC 22C3 pharmDx and the H&E staining should be performed on serial sections from the same paraffin block of the specimen.

Examine the H&E to determine if the specimen contains a minimum of 100 viable tumor cells.

A minimum of 100 viable tumor cells must be present in the PD-L1 stained slide for the specimen to be considered adequate for PD-L1 evaluation.

Instructions for Patient Specimens with Less Than 100 Viable Tumor Cells

Tissue from a deeper level of the block, or potentially another block, could present a sufficient number of viable tumor cells for PD-L1 IHC 22C3 pharmDx testing.

Evaluating Controls

PD-L1 IHC 22C3 pharmDx Control Cell Line Slide

Examine the PD-L1 IHC 22C3 pharmDx Control Cell Line Slide to determine that reagents are functioning properly.

Each slide contains sections of cell pellets with positive and negative PD-L1 expression (Figure 6). Assess the percentage of positive cells and the staining intensity. If any staining of the Control Cell Line Slide is not satisfactory, all results with the patient specimens should be considered invalid. Do not use the Control Cell Line Slide as an aid in interpretation of patient results.
Evaluate the overall staining intensity using the following guide:

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Negative</td>
</tr>
<tr>
<td>1+</td>
<td>Weak intensity</td>
</tr>
<tr>
<td>2+</td>
<td>Moderate intensity</td>
</tr>
<tr>
<td>3+</td>
<td>Strong intensity</td>
</tr>
</tbody>
</table>

**Positive Control Cell Pellet**

The following staining is acceptable for the PD-L1 positive cell pellet (Figure 7):

- At least 70% of the cells contain cell membrane staining of at least 2+ average staining intensity
- Any background staining is less than 1+ staining intensity

![Figure 7: Positive cell pellet with acceptable staining of PD-L1 IHC 22C3 pharmDx Control Cell Line Slide (20x magnification).](image)

**Negative Control Cell Pellet**

For the PD-L1 negative cell pellet, the following staining is acceptable (Figure 8):

- The majority of cells should demonstrate no staining. Note: The presence of 10 or fewer cells with distinct cell membrane staining is acceptable
- Any background staining is less than 1+ staining intensity

![Figure 8: Negative cell pellet with no staining of PD-L1 IHC 22C3 pharmDx Control Cell Line Slide (20x magnification).](image)

*Do not use the Control Cell Line Slide as an aid in interpretation of patient results.*
Positive and Negative In-house Control Tissue (NSCLC)

Examine the positive in-house NSCLC control tissue to determine that the tissues are correctly prepared and reagents are functioning properly. The ideal positive control tissue provides a complete dynamic representation of weak to moderate cell membrane staining (Figure 9). If staining of positive in-house control tissue is not satisfactory, all results with the patient specimen should be considered invalid.

![Figure 9: Ideal positive in-house control tissue (10x magnification).](image)

The ideal negative control tissue demonstrates no staining on tumor cells but contains tumor-associated macrophages/immune cells that express PD-L1 and offer an internal positive control (Figure 10). Examine the negative in-house control tissue to determine the expected staining. The variety of different cell types present in most tissue sections offers internal negative control sites; this should be verified by the user.

If unwanted staining occurs in the negative in-house control tissue, results with the patient specimen should be considered invalid.

![Figure 10: Ideal negative in-house control tissue (10x magnification).](image)
Optional Control Tissue

FFPE tonsil may also be used as an optional control specimen. Tonsil stained with PD-L1 should exhibit strong membrane staining in portions of the crypt epithelium and weak to moderate membrane staining of the follicular macrophages in the germinal centers (Figure 11).

PD-L1 expression of the endothelium, fibroblasts, and the surface epithelium should be negative.

![Image of Tonsil Stained with PD-L1 Primary Antibody](image)

Figure 11: Tonsil stained with PD-L1 primary antibody exhibiting strong membrane staining in portions of the crypt epithelium (A) and weak to moderate membrane staining of follicular macrophages in the germinal centers (B) (10x magnification).

Do not use in-house control tissue as an aid in interpretation of patient results.

Negative Control Reagent (NCR)

Examine the positive and negative in-house controls stained with the NCR to determine that reagents are functioning properly. Absence of cell membrane staining of viable tumor cells is satisfactory (Figure 12).

Examine the patient specimens stained with the NCR to determine if there is any non-specific staining that may interfere with interpreting the PD-L1 stained slide.

![Image of Absence of Cell Membrane Staining](image)

Figure 12: Absence of cell membrane staining in NSCLC stained with Negative Control Reagent (20x magnification).

The NCR indicates non-specific background staining and allows better interpretation of patient specimens stained with the primary antibody.
Verify Sample Acceptability

Tissue Block
3 serial sections are cut/prepared

Sections of 4–5 μm thickness are mounted on positively charged glass microscope slides

One section is stained with H&E (H&E Patient Specimen)
Is H&E slide acceptable?
(≥ 100 viable tumor cells)

Yes

No

Repeat staining run

Control Cell Line Slide acceptable?

Yes

No

Repeat staining run

Positive control tissue acceptable?

Yes

No

Repeat staining run

Negative control tissue acceptable?

Yes

No

Repeat staining run

Patient specimen stained with Negative Control Reagent acceptable?

Yes

No

Repeat staining run

Patient specimen stained with primary antibody exhibiting ≥ 100 viable tumor cells

Scoring by Pathologist

Exclude from scoring:
– Cytoplasmic staining
– Immune cells
– Normal cells
– Necrotic cells

Provide case report

Figure 13: Recommended order of slide evaluation.
Evaluate Staining and Determine Tumor Proportion Score

Definition of Tumor Proportion Score (TPS)

The Tumor Proportion Score is the percentage of viable tumor cells showing partial or complete membrane staining (≥ 1+) relative to all viable tumor cells present in the sample (positive and negative).

\[
TPS = \frac{\text{# PD-L1 positive tumor cells}}{\text{Total # of PD-L1 positive + PD-L1 negative tumor cells}}
\]

Evaluation of PD-L1 Staining

Score partial or complete cell membrane staining (≥ 1+) that is perceived distinct from cytoplasmic staining. Exclude cytoplasmic staining from scoring.

Score only viable tumor cells. Exclude all other cells from scoring: infiltrating immune cells, normal cells, necrotic cells, and debris.

Guidelines and Methods to Determine Tumor Proportion Score

- At low magnification, examine all well-preserved tumor areas. Evaluate overall areas of positive and negative tumor cells, keeping in mind that partial membrane staining or 1+ membrane staining may be difficult to see at low magnification. Ensure there are at least 100 viable tumor cells in the sample.
- At higher magnifications, including 10x, 20x, and 40x, observe all tumor areas with and without cell membrane staining.
- At this stage of working with multiple magnifications, primary analysis involves:
  - Distinguishing tumor cells from tumor-associated immune cells
  - Determining positive tumor areas and negative tumor areas
  - Determining partial and complete membrane staining ≥ 1+
- Calculate the Tumor Proportion Score by evaluating the percentage of PD-L1 positive tumor cells relative to all viable tumor cells present in the specimen.

**Note:** Carefully consider the overall tumor area without any perceptible and convincing cell membrane staining.
Make sure to *exclude* immune cells and necrotic tissue from scoring

The following considerations can help distinguish tumor cells from immune cells:

- Immune cells may have smaller nuclei than tumor cells
- Macrophages may contain pigmented particles in their cytoplasm
- Macrophages may have a scattered distribution. Pulmonary macrophages are present in the alveolar space
Scoring Guidelines

The TPS determines the PD-L1 expression of the specimen. See the table below for scoring guideline examples.

Table 1: TPS Expression Levels and Staining Characteristics

<table>
<thead>
<tr>
<th>Expression Level</th>
<th>TPS</th>
<th>Staining Pattern</th>
</tr>
</thead>
<tbody>
<tr>
<td>No PD-L1 Expression</td>
<td>&lt; 1%</td>
<td>Partial or complete cell membrane staining (≥ 1+) in &lt; 1% of viable tumor cells</td>
</tr>
<tr>
<td>PD-L1 Expression</td>
<td>1–49%</td>
<td>Partial or complete cell membrane staining (≥ 1+) in ≥ 1–49% of viable tumor cells</td>
</tr>
<tr>
<td>High PD-L1 Expression</td>
<td>≥ 50%</td>
<td>Partial or complete cell membrane staining (≥ 1+) in ≥ 50% of viable tumor cells</td>
</tr>
</tbody>
</table>
Suggested Methods for Determining TPS

Agilent recommends that scoring be performed within the context of the pathologist’s past experience and best judgment in interpreting IHC stains. We offer two different examples of techniques that may be used when considering various staining patterns to determine the respective Tumor Proportion Scores.

Example 1: Calculation of Combined Positive Score in a Small Tumor Area With Staining

At lower magnification: Evaluate the tumor area for any perceptible and convincing ≥ 1+ cell membrane staining.

**Assessment:** 10% of area with staining, 90% of area without staining

At higher magnification: Evaluate the area of staining to estimate the percentage of tumor cells that are PD-L1 positive and PD-L1 negative.

**Assessment:** 50% of these cells are PD-L1 positive

Calculate Tumor Proportion Score: Determine the overall percentage of PD-L1 positive stained tumor cells relative to the entire tumor area.

**Assessment: Tumor Proportion Score (TPS):**

10% x 50% = 5%

Figure 14: Example of tumor with small staining area.
Example 2: Calculation of Tumor Proportion Score in a Heterogeneous Tumor Area

At lower magnification: Visually divide the tumor area into sections.

At higher magnification: Observe tumor areas with cell membrane staining for percentage of stained cells in each section.

Assessment: Staining of tumor cells in each of the four respective sections: 80%, 25%, 50%, 100%

Calculate the Tumor Proportion Score: Determine the overall percentage of stained tumor cells.

Assessment: Tumor Proportion Score: 
\[(80\% + 25\% + 50\% + 100\%) / 4 = \geq 60\%

Figure 15: Example with heterogeneous tumor area.
Identifying Patients with NSCLC for Treatment

PD-L1 IHC 22C3 pharmDx is the only companion diagnostic indicated as an aid in identifying patients with NSCLC for treatment with KEYTRUDA® (pembrolizumab).

Clinical Validation of PD-L1 IHC 22C3 pharmDx in Previously Untreated Patients with NSCLC (First-line)

The clinical validity of PD-L1 IHC 22C3 pharmDx in identifying high PD-L1 expression (TPS ≥ 50%) in previously untreated patients with NSCLC is based on the KEYTRUDA KEYNOTE-024 study sponsored by Merck Sharp & Dohme Corp. Specimens from previously untreated patients with NSCLC were tested for PD-L1 expression using PD-L1 IHC 22C3 pharmDx. Only patients with TPS ≥ 50% were included in the KEYNOTE-024 study. Efficacy of KEYTRUDA treatment in patients selected by PD-L1 IHC 22C3 pharmDx is presented in the Clinical Performance Evaluation section on pages 70–75.

Table 2: PD-L1 Prevalencea in Patients with NSCLCb Screened for KEYNOTE-024c

<table>
<thead>
<tr>
<th>PD-L1 Expression</th>
<th>TPS &lt; 1%</th>
<th>TPS 1–49%</th>
<th>TPS ≥ 50%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevalence (n)</td>
<td>30.7% (507)</td>
<td>39.1% (646)</td>
<td>30.2% (500)</td>
</tr>
</tbody>
</table>

b. Patients screened for enrollment in KEYNOTE-024 NSCLC.
c. International phase 2/3 study comparing pembrolizumab with investigator’s choice platinum-containing (including pemetrexed+carboplatin, pemetrexed+cisplatin, gemcitabine+cisplatin, gemcitabine+carboplatin, or paclitaxel+carboplatin) in patients with non-small cell lung carcinoma who were previously untreated for advanced metastatic disease. ClinicalTrials.gov number NCT02142738.

Clinical Validation of PD-L1 IHC 22C3 pharmDx in Previously Treated Patients with NSCLC (Second-line and Beyond)

The clinical validity of PD-L1 IHC 22C3 pharmDx in identifying PD-L1 expression (TPS ≥ 1%) in previously treated patients with NSCLC is based on the KEYTRUDA KEYNOTE-010 study sponsored by Merck Sharp & Dohme Corp. Specimens from previously treated patients with NSCLC were tested for PD-L1 expression using PD-L1 IHC 22C3 pharmDx. Only patients with TPS ≥ 1% were included in the KEYNOTE-010 study. Efficacy of KEYTRUDA treatment in patients selected by PD-L1 IHC 22C3 pharmDx is presented in the Clinical Performance Evaluation section on pages 70–75.

Table 3: PD-L1 Prevalenced in Patients with NSCLCe Screened for KEYNOTE-010f

<table>
<thead>
<tr>
<th>PD-L1 Expression</th>
<th>TPS &lt; 1%</th>
<th>TPS 1–49%</th>
<th>TPS ≥ 50%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevalence (n)</td>
<td>43.0% (433)</td>
<td>34.2% (344)</td>
<td>22.8% (230)</td>
</tr>
</tbody>
</table>

e. Patients screened for enrollment in KEYNOTE-010 NSCLC.
f. International phase 2/3 study comparing pembrolizumab with docetaxel in patients with non-small cell lung carcinoma who have experienced disease progression after platinum-containing system therapy. ClinicalTrials.gov number NCT01905657.
Use the following flowchart to help you understand which patients are indicated for treatment with KEYTRUDA® based on their TPS and treatment history.

**PD-L1 IHC 22C3 pharmDx Testing Algorithm**

Figure 16: Testing algorithm for PD-L1 IHC 22C3 pharmDx.
Reporting Results

Suggested information to include when reporting results with PD-L1 IHC 22C3 pharmDx.

**PD-L1 IHC 22C3 pharmDx Summary of Sample Tested**

Date of Run: ________________________________

PD-L1 IHC 22C3 pharmDx Lot: ________________________________

Staining Run Log ID: ________________________________

Specimen ID: ________________________________

Patient Identifiers: ________________________________

Type of Service: IHC Stain with Manual Interpretation

Other: ________________________________

PD-L1 Included in Non-small Cell Lung Cancer Comprehensive Panel: Yes: ☐ No: ☐

Type of Tissue: Squamous Cell: ☐ Non-squamous Cell: ☐

**PD-L1 Testing Results**

Control Cell Line Slide Results: Pass: ☐ Fail: ☐

Adequate Tumor Cells Present (≥ 100 cells): ☐

**PD-L1 IHC 22C3 pharmDx Result to Treating Physician**

Tumor Proportion Score: ________________________________

TPS ≥ 50% (High PD-L1 expression): ☐ TPS 1–49% (PD-L1 expression): ☐ TPS < 1% (No PD-L1 expression): ☐

Comments to Treating Physician:

- KEYTRUDA® (pembrolizumab) as monotherapy is indicated for the first-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumors express PD-L1 with a ≥ 50% tumor proportion score (TPS) with no EGFR or ALK positive tumor mutations

- KEYTRUDA as monotherapy is indicated for the treatment of locally advanced or metastatic NSCLC in adults whose tumors express PD-L1 with a ≥ 1% TPS and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumor mutations should also have received targeted therapy before receiving KEYTRUDA
To successfully score PD-L1 IHC 22C3 pharmDx stained specimens, it is critical that:

- A minimum of 100 viable tumor cells are present for evaluation
- The appropriate cells are evaluated—only viable tumor cells should be scored
- The proper cellular localization is identified—only the membrane staining of tumor cells should be evaluated
- The staining is properly interpreted

The pathologist’s experience and judgment are important in the evaluation of PD-L1 staining. For evaluation of the immunohistochemical staining and scoring, objectives of 4x, 10x, 20x, and 40x magnifications (at a minimum) are appropriate.

However, below are several staining characteristic patterns that should be considered in the Tumor Proportion Score (TPS) assessment:

- Membrane staining of tumor cells at all intensities 1–3+ should be included
- Partial and/or complete membrane should be included
- Any perceptible and convincing membrane staining should be included
- Cytoplasmic staining should not be included
- Tumor-associated immune cells such as infiltrating lymphocytes or macrophages should not be included
- Granular staining must demonstrate a perceptible and convincing membrane pattern to be included

The following pages provide guidance on various staining characteristics.
Perceptible and Convincing Membrane Staining

Scoring should include any perceptible and convincing membrane staining (≥ 1+) at any magnification.

Review at higher magnification may be needed to confirm perceptible and convincing membrane staining.

**Key point**

Any perceptible and convincing membrane staining of tumor cells (≥ 1+) should be included in the TPS.
Weak Acceptable Membrane Staining

Scoring of tumor cells should include any perceptible and convincing membrane staining, including weak intensity of 1+.

**Figure 18a:** NSCLC stained with PD-L1 primary antibody exhibiting weak but perceptible and convincing membrane staining of tumor cells (20x magnification).

**Figure 18b:** NSCLC stained with PD-L1 primary antibody exhibiting weak but perceptible and convincing membrane staining of tumor cells (arrow) (40x magnification).

**Key point**

Weak but perceptible and convincing 1+ membrane staining of tumor cells should be included in the TPS.
Distinguishing Tumor Cells from Tumor-Associated Immune Cells (TAIC)
Scoring should only include all viable tumor cells with membrane staining ≥ 1+. Tumor-associated immune cells should be excluded from scoring.

Figure 19: NSCLC stained with PD-L1 primary antibody exhibiting strong staining of the TAIC (A) and lack of PD-L1 staining of tumor cells (B); TAIC staining should be excluded from the scoring (20x magnification).

Figure 20: NSCLC stained with PD-L1 primary antibody exhibiting strong staining of tumor cells (A) and moderate staining of the TAIC (B); TAIC staining should be excluded from the scoring (20x magnification).

**Key point**

Staining of TAIC should be excluded from the TPS
Heterogeneous Staining Intensities

Membrane staining of PD-L1 on NSCLC specimens is often heterogeneous with various staining intensities (1–3+).

![Image of heterogeneous staining intensities](image)

**Figure 21:** NSCLC stained with PD-L1 primary antibody exhibiting a heterogeneous membrane staining pattern with various staining intensities: 1+ staining (A), 2+ staining (B), and 3+ staining (C) (20x magnification).

**Key point**

All membrane staining of tumor cells, at all intensities 1–3+ should be included in the TPS

Partial vs. Complete Membrane Staining

Scoring should include viable tumor cells showing partial or complete membrane staining (≥ 1+).

![Image of partial vs. complete membrane staining](image)

**Figure 22:** NNSCLC stained with PD-L1 primary antibody exhibiting a heterogeneous membrane staining pattern with various staining intensities (1–3+): partial membrane staining of tumor cell (A) and complete cell membrane staining (B) (20x magnification).

**Key point**

Partial and/or complete membrane staining of tumor cells should be included in the TPS
Cytoplasmic and Membrane Staining

PD-L1 staining can exhibit cytoplasmic and/or membrane staining. Cytoplasmic staining should be excluded from the TPS scoring assessment.

**Figure 23:** NSCLC stained with PD-L1 primary antibody exhibiting strong cytoplasmic and membrane staining of tumor cells (20x magnification).

**Key point**

Only membrane staining of tumor cells should be included in the TPS

Granular Staining

PD-L1 membrane staining may be indistinguishable when the staining pattern appears granular. Granular staining can be difficult to interpret and easily confused with cytoplasmic staining. Only perceptible and convincing granular membrane staining should be included in the TPS scoring.

**Figure 24:** NSCLC specimen stained with PD-L1 primary antibody with the majority of tumor cells exhibiting a granular pattern of perceptible and convincing membrane staining (20x magnification).

**Key point**

Granular staining of tumor cells must be perceptibly and convincingly membranous to be included in the TPS
Patchy Staining
Staining of PD-L1 on NSCLC specimens may be patchy in appearance. A review of each portion of the specimen at high power may be needed to score accurately.

Figure 25: NSCLC stained with PD-L1 primary antibody exhibiting a patchy membrane staining pattern (10x magnification).

Key point
Assess entire specimen to accurately determine the TPS

Anthracotic Pigment
Anthracotic pigment is an accumulation of carbon in the lungs from inhaled smoke or coal dust. It appears as granular dark spots and is often helpful to distinguish tumor cells from TAIC, as anthracotic pigment is found within pulmonary macrophages and not within tumor cells.

Figure 26: NSCLC stained with PD-L1 primary antibody exhibiting strong staining of tumor cells (A) and moderate staining of the TAIC (B); TAIC staining should be excluded from the scoring (20x magnification)

Key point
Anthracotic pigment should be disregarded
Case 1: TPS < 1%

Figure 27a: 10x magnification

Figure 27b: 20x magnification

Figure 27c: 40x magnification

Figure 27a–27c: NSCLC specimen stained with PD-L1 antibody exhibiting TPS < 1%.
Case 2: TPS < 1%

Figure 28a: 10x magnification

Figure 28b: 20x magnification

Figure 28c: 40x magnification

Figure 28a–28c: NSCLC specimen stained with PD-L1 antibody exhibiting TPS < 1%.
Case 3: TPS < 1%

Figure 29a: 10x magnification

Figure 29b: 20x magnification

Figure 29c: 40x magnification

**Figure 29a–29c:** NSCLC specimen stained with PD-L1 antibody exhibiting TPS < 1%. TAIC are staining, but should be excluded from scoring.
Case 4: TPS < 1%

Figure 30a: 10x magnification

Figure 30b: 20x magnification

Figure 30c: 40x magnification

Figure 30a–30c: NSCLC specimen stained with PD-L1 antibody exhibiting TPS < 1%. TAIC are staining, but should be excluded from scoring.
Case 5: TPS 1–49%

Figure 31a: 10x magnification

Figure 31b: 20x magnification

Figure 31c: 40x magnification

Figure 31a–31c: NSCLC specimen stained with PD-L1 antibody exhibiting TPS 1–49%.
Case 6: TPS 1–49%

Figure 32a: 10x magnification

Figure 32b: 20x magnification

Figure 32c: 40x magnification

Figure 32a–32c: NSCLC specimen stained with PD-L1 antibody exhibiting TPS 1–49%.
Case 7 TPS 1–49%

**Figure 33a**: 10x magnification

**Figure 33b**: 20x magnification

**Figure 33c**: 40x magnification

**Figure 33a–33c**: NSCLC specimen stained with PD-L1 antibody exhibiting TPS 1–49%.
Case 8: TPS 1–49%

Figure 34a: 10x magnification

Figure 34b: 20x magnification

Figure 34c: 40x magnification

Figure 34a–34c: NSCLC specimen stained with PD-L1 antibody exhibiting TPS 1–49%.
Case 9: TPS ≥ 50%

Figure 35a: 10x magnification

Figure 35b: 20x magnification

Figure 35c: 40x magnification

Figure 35a–35c: NSCLC specimen stained with PD-L1 antibody exhibiting TPS ≥ 50%.
Case 10: TPS ≥ 50%

Figure 36a: 10x magnification

Figure 36b: 20x magnification

Figure 36c: 40x magnification

Figure 36a–36c: NSCLC specimen stained with PD-L1 antibody exhibiting TPS ≥ 50%.
Case 11: TPS ≥ 50%

Figure 37a: 10x magnification

Figure 37b: 20x magnification

Figure 37c: 40x magnification

Figure 37a–37c: NSCLC specimen stained with PD-L1 antibody exhibiting TPS ≥ 50%.
Case 12: TPS ≥ 50%

Figure 38a: 10x magnification

Figure 38b: 20x magnification

Figure 38c: 40x magnification

Figure 38a–38c: NSCLC specimen stained with PD-L1 antibody exhibiting TPS ≥ 50%.
Case 13: TPS ≥ 50%

Figure 39a–39c: NSCLC specimen stained with PD-L1 antibody exhibiting TPS ≥ 50%.
Case 14: TPS ≥ 50%

Figure 40a: 10x magnification

Figure 40b: 20x magnification

Figure 40c: 40x magnification

Figure 40a–40c: NSCLC specimen stained with PD-L1 antibody exhibiting TPS ≥ 50%.
Case 15: TPS ≥ 50%

Figure 41a: 10x magnification

Figure 41b: 20x magnification

Figure 41c: 40x magnification

Figure 41a–41c: NSCLC specimen stained with PD-L1 antibody exhibiting TPS ≥ 50%.
Challenging Case 1: Near ≥ 50% Cut-off (TPS 40–60%)

Figure 42a: 10x magnification

Figure 42b: 20x magnification

Figure 42c: 40x magnification

Figure 42a–42c: NSCLC specimen stained with PD-L1 antibody exhibiting TPS 40%.
Challenging Case 2: Near ≥ 50% Cut-off (TPS 40–60%)

Figure 43a: 10x magnification

Figure 43b: 20x magnification

Figure 43c: 40x magnification

Figure 43a–43c: NSCLC specimen stained with PD-L1 antibody exhibiting TPS 40%.
Challenging Case 3: Near ≥ 50% Cut-off (TPS 40–60%)

Figure 44a: 10x magnification

Figure 44b: 20x magnification

Figure 44c: 40x magnification

Figure 44a–44c: NSCLC specimen stained with PD-L1 antibody exhibiting TPS 50%.
Challenging Case 4: Near ≥ 50% Cut-off (TPS 40–60%)

Figure 45a–45c: NSCLC specimen stained with PD-L1 antibody exhibiting TPS 60%.
Challenging Case 5: Near ≥ 50% Cut-off (TPS 40–60%)

Figure 46a–46c: NSCLC specimen stained with PD-L1 antibody exhibiting TPS 60%.
Challenging Case 6: Near ≥ 1% Cut-off (TPS 0–10%)

Figure 47a: 10x magnification

Figure 47b: 20x magnification

Figure 47c: 40x magnification

Figure 47a–47c: NSCLC specimen stained with PD-L1 antibody exhibiting TPS < 1%.
Challenging Case 7: Near ≥ 1% Cut-off (TPS 0–10%)

Figure 48a: 10x magnification

Figure 48b: 20x magnification

Figure 48c: 40x magnification

Figure 48a–48c: NSCLC specimen stained with PD-L1 antibody exhibiting TPS < 1%.
Challenging Case 8: Near ≥ 1% Cut-off (TPS 0–10%)

Figure 49a–49c: NSCLC specimen stained with PD-L1 antibody exhibiting TPS 1–10%.
Challenging Case 9: Near ≥ 1% Cut-off (TPS 0–10%)

Figure 50a: 10x magnification

Figure 50b: 20x magnification

Figure 50c: 40x magnification

**Figure 50a–50c:** NSCLC specimen stained with PD-L1 antibody exhibiting TPS 1–10%.
Challenging Case 10: Near ≥ 1% Cut-off (TPS 0–10%)

Figure 51a: 10x magnification

Figure 51b: 20x magnification

Figure 51c: 40x magnification

Figure 51a–51c: NSCLC specimen stained with PD-L1 antibody exhibiting TPS 1–10%.
Artifacts

The following pages provide examples of artifacts you may see when staining with PD-L1 IHC 22C3 pharmDx.

Non-specific Background Staining

Background staining is defined as diffuse, non-specific staining of a specimen. It is caused by several factors. These factors include, but are not limited to, pre-analytic fixation and processing of the specimen, incomplete removal of paraffin from sections, and incomplete rinsing of slides during staining.

The use of fixatives other than neutral buffered formalin may be a source of background staining. Background staining with PD-L1 IHC 22C3 pharmDx is rare.

Possible Causes of Background

- Improper drying of slides; ensure slides remain wet with buffer while loading onto Autostainer Link 48 and prior to initiating run
- Improper deparaffinization procedure
- Incomplete rinsing of reagents from slides

The non-specific background staining of the negative test specimen is useful in determining the level of background staining in the positive test specimen. All specimens must have \( \leq 1+ \) non-specific background staining.

Key point

All specimens must have \( \leq 1+ \) non-specific background staining

Figure 52: NSCLC stained with PD-L1 primary antibody exhibiting acceptable non-specific background staining (20x magnification).
Figure 53: NSCLC stained with PD-L1 primary antibody exhibiting unacceptable non-specific background staining (> 1+) (20x magnification).

Figure 54: NSCLC stained with Negative Control Reagent (NCR) exhibiting acceptable non-specific background staining (20x magnification).
Edge Artifact

Commonly, edge artifacts are linked to the pre-analytic handling of the tissue.

- Inadequate processing of thick tissue samples may mimic edge artifact by rendering the central portion of the tissue sub-optimally fixed relative to the peripheral areas. In these circumstances, the immunoreactivity based on the sub-optimal central portion may be mistakenly interpreted as false-negative as optimal fixation is only present at the periphery.
- Frequently, increased staining is observed around the periphery of the tissue specimen, known as the "edge artifact".
- Edge artifacts can be due to drying of the tissue specimen prior to fixation or during the staining procedure.
- If the positive reaction is only at the edge of the tissue section (i.e., a few cell layers of staining at the periphery and ending abruptly with penetration into the centrally located tumor), scoring at the edge of the tissue specimen should be avoided.

**Key point**

*Scoring of the edge of a specimen should be avoided if staining is inconsistent with the rest of the specimen.*

*Figure 55a: NSCLC stained with PD-L1 primary antibody exhibiting edge artifact staining. Edge staining should be excluded from the scoring (4x magnification).*
Figure 55b: NSCLC stained with PD-L1 primary antibody exhibiting edge artifact staining; edge staining should be excluded from the scoring (20x magnification).
Crush Artifact

Crush artifact is closely related to edge artifact. This artifact may be encountered more often in transbronchial biopsies. The compression of the tissues along the edges of the specimen can produce a linear staining that has to be interpreted as an artifact.

- Inadvertent crushing of the tissue occasionally occurs during sectioning, resulting in morphologically distorted cellular architecture
  
- When compared to surrounding cells, stronger staining may be observed in crushed cells. Crushed cells typically demonstrate condensed nuclei. Crushed cells should be avoided in scoring

**Key point**

Scoring of crush artifact should be avoided if staining is inconsistent with entire specimen

*Figure 56: NSCLC stained with PD-L1 primary antibody exhibiting crush artifact (10x magnification).*
Necrosis

Necrosis can be described as morphological changes indicative of cell death with undefined cellular detail. Necrosis is often present in non-small cell lung cancer specimens and should be excluded from scoring.

**Key point**

Scoring of necrotic areas should be excluded from the TPS

Figure 57: NSCLC stained with PD-L1 primary antibody exhibiting strong staining of necrosis and viable tumor cells; necrosis staining should be excluded from the scoring (20x magnification).
Poor Fixation

Standardization of fixation is very important when using PD-L1 IHC 22C3 pharmDx. Sub-optimal fixation on tissues may give erroneous results.

**Key point**

Proper fixation is important for accurate diagnosis

![Figure 58: NSCLC stained with PD-L1 primary antibody exhibiting poor tissue fixation (10x magnification).](image)
### Troubleshooting Guidelines for PD-L1 IHC 22C3 pharmDx

For further troubleshooting help, contact your local Agilent representative.

<table>
<thead>
<tr>
<th>Problem</th>
<th>Probable Cause</th>
<th>Suggested Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>No staining of slides</td>
<td>Programming error</td>
<td>Verify that the PD-L1 IHC 22C3 pharmDx program was selected for programming of slides</td>
</tr>
<tr>
<td></td>
<td>Lack of reaction with DAB+ Substrate-Chromogen Solution (DAB)</td>
<td>Verify that DAB+ Substrate-Chromogen Solution was prepared properly</td>
</tr>
<tr>
<td></td>
<td>Sodium azide in wash buffer</td>
<td>Use only Dako Wash Buffer (Code K8007)</td>
</tr>
<tr>
<td></td>
<td>Degradation of Control Slide</td>
<td>Check kit expiration date and kit storage conditions on outside of package</td>
</tr>
<tr>
<td>Weak staining of specimen slides</td>
<td>Inappropriate fixation method used</td>
<td>Ensure that only neutral buffered formalin fixative and approved fixation methods are used</td>
</tr>
<tr>
<td></td>
<td>Insufficient reagent volume applied</td>
<td>Check size of tissue section and reagent volume applied</td>
</tr>
<tr>
<td></td>
<td>Inappropriate wash buffer used</td>
<td>Use only Dako Wash Buffer, Code K8007</td>
</tr>
<tr>
<td>Weak staining of specimen slides or of the positive cell line pellet on the Dako-provided Control Cell Line Slide</td>
<td>Inadequate target retrieval</td>
<td>Verify that the 3-in-1 pre-treatment procedure was correctly performed</td>
</tr>
<tr>
<td></td>
<td>Inappropriate wash buffer used</td>
<td>Use only Dako Wash Buffer, Code K8007</td>
</tr>
<tr>
<td>Excessive background staining of slides</td>
<td>Paraffin incompletely removed</td>
<td>Verify that the 3-in-1 pre-treatment procedure was correctly performed</td>
</tr>
<tr>
<td></td>
<td>Slides dried while loading onto Autostainer Link 48</td>
<td>Ensure slides remain wet with buffer while loading and prior to initiating run</td>
</tr>
<tr>
<td></td>
<td>Non-specific binding of reagents to tissue section</td>
<td>Check for proper fixation of the specimen and/or the presence of necrosis</td>
</tr>
<tr>
<td></td>
<td>Inappropriate fixation method used</td>
<td>Ensure that only neutral buffered formalin fixative and recommended fixation methods are used</td>
</tr>
<tr>
<td>Tissue detached from slides</td>
<td>Use of incorrect microscope slides</td>
<td>Use Dako FLEX IHC Microscope Slides (Code K8020), or charged slides (such as Fisherbrand Superfrost Plus)</td>
</tr>
<tr>
<td></td>
<td>Inadequate preparation of specimens</td>
<td>Cut sections should be placed in a 58 ± 2 °C oven for 1 hour prior to staining</td>
</tr>
<tr>
<td>Excessively strong specific staining</td>
<td>Inappropriate fixation method used</td>
<td>Ensure that only approved fixatives and fixation methods are used</td>
</tr>
<tr>
<td></td>
<td>Inappropriate wash buffer used</td>
<td>Use only Dako Wash Buffer (Code K8007)</td>
</tr>
<tr>
<td>Target Retrieval Solution is cloudy in appearance when heated</td>
<td>When heated, the Target Retrieval Solution turns cloudy in appearance</td>
<td>This is normal and does not influence staining</td>
</tr>
</tbody>
</table>

**Note:** If the problem cannot be attributed to any of the above causes, or if the suggested corrective action fails to resolve the problem, please call Agilent Technical Support for further assistance. Additional information on staining techniques and specimen preparation can be found in Dako Education Guide: Immunohistochemical Staining Methods (5) (available from Agilent).
KEYNOTE-024: Controlled trial of NSCLC patients naïve to treatment

The safety and efficacy of pembrolizumab were investigated in KEYNOTE-024, a multicenter, controlled study for the treatment of previously untreated metastatic NSCLC. Patients had PD-L1 expression with a ≥ 50% Tumor Proportion Score (TPS) based on PD-L1 IHC 22C3 pharmDx. Patients were randomised (1:1) to receive pembrolizumab at a dose of 200 mg every 3 weeks (n=154) or investigator’s choice platinum-containing chemotherapy (n=151; including pemetrexed+carboplatin, pemetrexed+cisplatin, gemcitabine+cisplatin, gemcitabine+carboplatin, or paclitaxel+carboplatin. Non-squamous patients could receive pemetrexed maintenance). Patients were treated with pembrolizumab until unacceptable toxicity or disease progression. Treatment could continue beyond disease progression if the patient was clinically stable and was considered to be deriving clinical benefit by the investigator. The study excluded patients with EGFR or ALK genomic tumor aberrations; autoimmune disease that required systemic therapy within 2 years of treatment; a medical condition that required immunosuppression; or who had received more than 30 Gy of thoracic radiation within the prior 26 weeks. Assessment of tumor status was performed every 9 weeks. Patients on chemotherapy who experienced independently-verified progression of disease were able to crossover and receive pembrolizumab.

Table 4: Efficacy Results in KEYNOTE-024

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>KEYTRUDA 200 mg every 3 weeks, n=154</th>
<th>Chemotherapy n=151</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFS*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number (% of patients with event)</td>
<td>73 (47%)</td>
<td>116 (77%)</td>
</tr>
<tr>
<td>Hazard ratio† (95% CI)</td>
<td>0.50 (0.37, 0.68)</td>
<td>--</td>
</tr>
<tr>
<td>p-Value‡</td>
<td>&lt;0.001</td>
<td>--</td>
</tr>
<tr>
<td>Median in months (95% CI)</td>
<td>10.3 (6.7, NA)</td>
<td>6.0 (4.2, 6.2)</td>
</tr>
<tr>
<td>OS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number (% of patients with event)</td>
<td>44 (29%)</td>
<td>64 (42%)</td>
</tr>
<tr>
<td>Hazard ratio† (95% CI)</td>
<td>0.60 (0.41, 0.89)</td>
<td>--</td>
</tr>
<tr>
<td>p-Value‡</td>
<td>0.005</td>
<td>--</td>
</tr>
<tr>
<td>Median in months (95% CI)</td>
<td>Not reached (NA, NA)</td>
<td>Not reached (9.4, NA)</td>
</tr>
<tr>
<td>Objective Response Rate*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ORR % (95% CI)</td>
<td>45% (37, 53)</td>
<td>28% (21, 36)</td>
</tr>
<tr>
<td>Complete response %</td>
<td>4%</td>
<td>1%</td>
</tr>
<tr>
<td>Partial response %</td>
<td>41%</td>
<td>27%</td>
</tr>
<tr>
<td>Response Duration§</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median in month (range)</td>
<td>Not reached (1.9+, 14.5+)</td>
<td>6.3(2.1+,12.6+)</td>
</tr>
<tr>
<td>% with duration ≥ 6 months</td>
<td>88%</td>
<td>59%*</td>
</tr>
</tbody>
</table>

* Assessed by BICR using RECIST 1.1
† Hazard ratio (KEYTRUDA compared to chemotherapy) based on the stratified Cox proportional hazard model
‡ Based on stratified Log rank test
§ Based on patients with a best overall response as confirmed complete or partial response
¶ Based on Kaplan-Meier estimates; includes 43 patients with responses of 6 months or longer
# Based on Kaplan-Meier estimates; includes 16 patients with responses of 6 months or longer
NA = not available
Among the 305 patients in KEYNOTE-024, baseline characteristics were: median age 65 years (54% age 65 or older); 61% male; 82% White and 15% Asian; and ECOG performance status 0 and 1 in 35% and 65%, respectively. Disease characteristics were squamous (18%) and non-squamous (82%); M1 (99%); and brain metastases (9%).

The primary efficacy outcome measure was progression-free survival (PFS) as assessed by blinded independent central review (BICR) using Response Evaluation Criteria on Solid Tumors Version 1.1 (RECIST 1.1). Secondary efficacy outcome measures were overall survival (OS) and objective response rate (ORR) as assessed by BICR using RECIST 1.1. Table 4 summarizes key efficacy measures for the entire intent to treat (ITT) population.

Figure 59: Kaplan-Meier Curve for Overall Survival in Trial 24.
KEYNOTE-010: Controlled trial of NSCLC patients previously treated with chemotherapy

The clinical benefit of PD-L1 IHC 22C3 pharmDx was investigated in KEYNOTE-010, a multicenter, open-label, randomized clinical study conducted to assess the safety and efficacy of KEYTRUDA® in patients with advanced NSCLC previously treated with platinum-containing chemotherapy. Patients had PD-L1 expression with a ≥ 1% TPS based on a clinical trial assay (CTA) version of PD-L1 IHC 22C3 pharmDx. Patients with EGFR activation mutation or ALK translocation also had disease progression on approved therapy for these mutations prior to receiving pembrolizumab. Patients were randomised (1:1:1) to receive pembrolizumab at a dose of 2 (n=344) or 10 mg/kg (n=346) every 3 weeks or docetaxel at a dose of 75 mg/m2 every 3 weeks (n=343) until disease progression or unacceptable toxicity. The trial excluded patients with autoimmune disease; a medical condition that required immunosuppression; or who had received more than 30 Gy of thoracic radiation within the prior 26 weeks. Assessment of tumor status was performed every 9 weeks. The primary efficacy outcome measures were OS and PFS as assessed by BICR using RECIST 1.1.

Based on the CTA, a total of 1,033 NSCLC patients were randomized in the study. To evaluate the clinical utility of PD-L1 IHC 22C3 pharmDx, archived clinical study samples were retrospectively tested at a US based reference laboratory with PD-L1 IHC 22C3 pharmDx. Out of the 1,033 patients, tumor tissue from 529 patients was retrospectively tested with the PD-L1 IHC 22C3 pharmDx test. Specimens from 413 patients had PD-L1 expression (≥ 1% of viable tumor cells exhibiting membrane staining at any intensity) and samples from 94 patients did not have PD-L1 expression (< 1% of viable tumor cells exhibiting membrane staining at any intensity). Within these 413 patients with PD-L1 expression, specimens from 163 patients had high PD-L1 expression (≥ 50% of viable tumor cells exhibiting membrane staining at any intensity).

The level of agreement achieved between the CTA and PD-L1 IHC 22C3 pharmDx is shown in Table 5.

Among randomized patients having PD-L1 expression by PD-L1 IHC 22C3 pharmDx, the demographic and other baseline characteristics were well balanced between the treatment arms. The median age was 63 years (44% age 65 or older). The majority of patients were white (77%) and male (58%); baseline ECOG performance status was 0 (29%) or 1 (71%). Seventy-eight percent (78%) of patients were former/current smokers. Twenty-two percent (22%) of patients had squamous histology and 69% had non-squamous histology. The baseline and demographic characteristics were similarly well balanced across pembrolizumab and docetaxel arms in the overall clinical study.

Table 5: CTA vs. PD-L1 IHC 22C3 pharmDx Agreement

<table>
<thead>
<tr>
<th>Agreement Rates</th>
<th>PD-L1 Cut-off</th>
<th>Negative Percent Agreement (95% Confidence Interval (CI))</th>
<th>Positive Percent Agreement (95% Confidence Interval (CI))</th>
</tr>
</thead>
<tbody>
<tr>
<td>CTA vs. PD-L1 IHC 22C3 pharmDx</td>
<td>TPS ≥ 1%</td>
<td>94.5% [91.4%–96.6%]</td>
<td>80.0% [76.9%–82.8%]</td>
</tr>
<tr>
<td></td>
<td>TPS ≥ 50%</td>
<td>98.3% [97.1%–99.0%]</td>
<td>73.2% [67.9%–77.9%]</td>
</tr>
</tbody>
</table>
Table 6: Response to KEYTRUDA in Previously Treated NSCLC Patients: Overall Clinical Study and PD-L1 IHC 22C3 pharmDx Positive Patients: PD-L1 TPS ≥ 1%

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>KEYTRUDA 2 mg/kg every 3 weeks</th>
<th>KEYTRUDA 10 mg/kg every 3 weeks</th>
<th>Docetaxel 75 mg/m² every 3 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Clinical Trial</td>
<td>PD-L1 IHC 22C3 pharmDx</td>
<td>Clinical Trial</td>
</tr>
<tr>
<td>Number of Patients</td>
<td>344</td>
<td>140</td>
<td>346</td>
</tr>
<tr>
<td>OS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deaths (%)</td>
<td>172 (50%)</td>
<td>59 (42%)</td>
<td>156 (45%)</td>
</tr>
<tr>
<td>Hazard ratio* (95% CI)</td>
<td>0.71 (0.58, 0.88)</td>
<td>0.54 (0.37, 0.78)</td>
<td>0.61 (0.49, 0.75)</td>
</tr>
<tr>
<td>p-Value*</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Median in months (95% CI)</td>
<td>10.4 (9.4, 11.9)</td>
<td>11.8 (9.6, NA)</td>
<td>12.7 (10.0, 17.3)</td>
</tr>
<tr>
<td>Hazard ratio* (95% CI)</td>
<td>0.71 (0.58, 0.88)</td>
<td>0.54 (0.37, 0.78)</td>
<td>0.61 (0.49, 0.75)</td>
</tr>
<tr>
<td>p-Value*</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Median in months (95% CI)</td>
<td>10.4 (9.4, 11.9)</td>
<td>11.8 (9.6, NA)</td>
<td>12.7 (10.0, 17.3)</td>
</tr>
<tr>
<td>Hazard ratio* (95% CI)</td>
<td>0.71 (0.58, 0.88)</td>
<td>0.54 (0.37, 0.78)</td>
<td>0.61 (0.49, 0.75)</td>
</tr>
<tr>
<td>p-Value*</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Median in months (95% CI)</td>
<td>10.4 (9.4, 11.9)</td>
<td>11.8 (9.6, NA)</td>
<td>12.7 (10.0, 17.3)</td>
</tr>
<tr>
<td>Hazard ratio* (95% CI)</td>
<td>0.71 (0.58, 0.88)</td>
<td>0.54 (0.37, 0.78)</td>
<td>0.61 (0.49, 0.75)</td>
</tr>
<tr>
<td>p-Value*</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Median in months (95% CI)</td>
<td>10.4 (9.4, 11.9)</td>
<td>11.8 (9.6, NA)</td>
<td>12.7 (10.0, 17.3)</td>
</tr>
</tbody>
</table>

* Hazard ratio (KEYTRUDA compared to docetaxel) based on the stratified Cox proportional hazard model; * Based on stratified Log rank test; ‡ Assessed by BICR using RECIST 1.1; § All responses were partial responses

Table 7: Response to KEYTRUDA in Previously Treated NSCLC Patients: Overall Clinical Study and PD-L1 IHC 22C3 pharmDx Positive Patients: PD-L1 TPS ≥ 50%

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>KEYTRUDA 2 mg/kg every 3 weeks</th>
<th>KEYTRUDA 10 mg/kg every 3 weeks</th>
<th>Docetaxel 75 mg/m² every 3 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Clinical Trial</td>
<td>PD-L1 IHC 22C3 pharmDx</td>
<td>Clinical Trial</td>
</tr>
<tr>
<td>Number of Patients</td>
<td>139</td>
<td>56</td>
<td>151</td>
</tr>
<tr>
<td>OS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deaths (%)</td>
<td>58 (42%)</td>
<td>18 (32%)</td>
<td>60 (40%)</td>
</tr>
<tr>
<td>Hazard ratio* (95% CI)</td>
<td>0.54 (0.38, 0.77)</td>
<td>0.45 (0.24, 0.84)</td>
<td>0.50 (0.36, 0.70)</td>
</tr>
<tr>
<td>p-Value*</td>
<td>&lt;0.001</td>
<td>0.00541</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Median in months (95% CI)</td>
<td>14.9 (10.4, NA)</td>
<td>Not reached (9.3, NA)</td>
<td>17.3 (11.8, NA)</td>
</tr>
<tr>
<td>Hazard ratio* (95% CI)</td>
<td>0.54 (0.38, 0.77)</td>
<td>0.45 (0.24, 0.84)</td>
<td>0.50 (0.36, 0.70)</td>
</tr>
<tr>
<td>p-Value*</td>
<td>&lt;0.001</td>
<td>0.00541</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Median in months (95% CI)</td>
<td>14.9 (10.4, NA)</td>
<td>Not reached (9.3, NA)</td>
<td>17.3 (11.8, NA)</td>
</tr>
<tr>
<td>Hazard ratio* (95% CI)</td>
<td>0.54 (0.38, 0.77)</td>
<td>0.45 (0.24, 0.84)</td>
<td>0.50 (0.36, 0.70)</td>
</tr>
<tr>
<td>p-Value*</td>
<td>&lt;0.001</td>
<td>0.00541</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Median in months (95% CI)</td>
<td>14.9 (10.4, NA)</td>
<td>Not reached (9.3, NA)</td>
<td>17.3 (11.8, NA)</td>
</tr>
<tr>
<td>Hazard ratio* (95% CI)</td>
<td>0.54 (0.38, 0.77)</td>
<td>0.45 (0.24, 0.84)</td>
<td>0.50 (0.36, 0.70)</td>
</tr>
<tr>
<td>p-Value*</td>
<td>&lt;0.001</td>
<td>0.00541</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Median in months (95% CI)</td>
<td>14.9 (10.4, NA)</td>
<td>Not reached (9.3, NA)</td>
<td>17.3 (11.8, NA)</td>
</tr>
</tbody>
</table>

* Hazard ratio (KEYTRUDA compared to docetaxel) based on the stratified Cox proportional hazard model; * Based on stratified Log rank test; ‡ Assessed by BICR using RECIST 1.1; § All responses were partial responses
Efficacy results are summarized in Tables 6 and 7. KEYTRUDA® demonstrated durable clinical benefit in NSCLC patients with PD-L1 expression (TPS ≥ 1%), which was enhanced in patients with high PD-L1 expression (TPS ≥ 50%), as determined by PD-L1 IHC 22C3 pharmDx. The magnitude of benefit was comparable to that in the overall clinical trial. The tables on page 73 summarize key efficacy measures in the overall population with PD-L1 expression (TPS ≥ 1%) and in the high PD-L1 expression (TPS ≥ 50%) subset for the overall clinical study (TPS ≥ 1% by CTA) and in the population with PD-L1 expression by PD-L1 IHC 22C3 pharmDx. The Kaplan-Meier curve for OS (TPS ≥ 1%), as determined by PD-L1 IHC 22C3 pharmDx is shown in Figure 60. Efficacy results were similar for the 2 mg/kg and 10 mg/kg KEYTRUDA arms.

Additional robustness analyses were conducted to consider the potential impact of missing data arising from patients with PD-L1 expression (TPS ≥ 1%) by PD-L1 IHC 22C3 pharmDx, but who may have had no PD-L1 expression (TPS < 1%) by the CTA. Patients with such test results are part of the intended use/ intent to diagnose (ITD)/ population of PD-L1 IHC 22C3 pharmDx; however, they were excluded from the clinical trial due to no PD-L1 expression upon CTA screening. To account for these missing data, a sensitivity analysis was conducted to understand the plausible range for the hazard ratio (HR) estimated based on PD-L1 IHC 22C3 pharmDx in the TPS ≥ 1% and TPS ≥ 50% subpopulations under an ITD framework to verify the consistency with the observed HR based on enrollment with the CTA. The HR sensitivity analysis results showed that the HR estimates are robust to any assumed attenuation of the treatment effect under the ITD framework.
Figure 60: Kaplan-Meier Curve for Overall Survival by Treatment Arm (TPS ≥ 1% by PD-L1 IHC 22C3 pharmDx, Intent to Treat Population).
References

For PD-L1 testing,
Choose PD-L1 IHC 22C3 pharmDx—the ONE assay clinical trial-proven with KEYTRUDA® (pembrolizumab)

The ONE assay used to assess PD-L1 across KEYTRUDA clinical trials

The ONE assay established with KEYTRUDA in the pivotal NSCLC studies

The ONE assay CE-IVD—marked as an aid in identifying urothelial carcinoma patients for treatment with KEYTRUDA

In ONE all-inclusive kit that delivers reproducible, repeatable, and clinically validated results for diagnostic confidence

Learn more:
https://www.agilent.com/chem/PDL122C3

Europe
info_agilent@agilent.com

For countries outside of the European Union, see the local KEYTRUDA product label for approved indications and expression cutoff values to guide therapy.

This information is subject to change without notice.

© Agilent Technologies, Inc. 2019
Published in the USA, October 23, 2019
29171 2019OCT23